PMC:7507645 / 20764-21258 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/7507645","sourcedb":"PMC","sourceid":"7507645","source_url":"https://www.ncbi.nlm.nih.gov/pmc/7507645","text":"Reductions in PHQ-9 scores were observed, regardless of MO at baseline (with MO: quarterly − 2.8 [0.4], monthly − 2.3 [0.4] vs placebo − 2.4 [0.4]; without MO: quarterly − 2.6 [0.4], monthly − 2.3 [0.4] vs placebo − 1.6 [0.4]; Table 2). Numerically larger reductions were generally observed in the fremanezumab-treated groups compared with placebo; however, the only significant difference was observed in patients without MO in the fremanezumab quarterly group compared with placebo (Table 2).","tracks":[]}